Project Grant R01DA061223

Award Date 6/15/24
Completion Date 4/30/29
Dollars Obligated $2.3M
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding a $395,995 longitudinal study to examine the bidirectional relationship between cannabis use, sleep, and the hypothalamic-pituitary-adrenal (HPA) axis. The study, conducted by Oregon Health & Science University, will enroll 60 participants aged 21-29 to assess daily sleep behaviors, cannabis use, and motivations using ecological momentary...
This Project Grant award of $443,263 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to characterize the unique effects of recreational cannabis use on sleep in women of childbearing age. The 5-year study, beginning September 2024, will examine the relationship between cannabis use and sleep, investigating the mediating role of stress physiology and reproductive hormones. The research will utilize a within-subject design...
This $2,219,415 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research investigating the bidirectional relationship between circadian rhythms and cannabinoid use. The primary objectives are to: 1) determine how cannabinoid self-administration affects cell type-specific molecular rhythms in the nucleus accumbens and sleep/wake rhythms in a rat model; 2) assess whether cell type-specific...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,178,880 to the University of Washington to conduct research on the "MODELING WEEKLY AND DAILY PROCESSES OF A HIGH-RISK FEEDBACK CYCLE OF ALCOHOL, CANNABIS, AND NONMEDICAL USE OF PRESCRIPTION STIMULANTS IN COLLEGE STUDENTS: IMPACTS ON USE, ACADEMICS, AND SLEEP." The project aims to examine the mechanisms underlying the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Federal Grant Program for Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,185,966 to the University of Mississippi Medical Center (UMMC) to investigate the relationship between short sleep duration and methamphetamine use. The project aims to: 1) evaluate how dysregulation of the orexin (hypocretin) neurotransmitter system underlies short sleep phenotypes in female rhesus monkeys; 2) assess...
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a randomized crossover trial to evaluate the ability of 36 regular cannabis consumers to self-titrate their tetrahydrocannabinol (THC) dose when vaping cannabis concentrates of varying potencies (30%, 60%, and 90% THC). The $286,984 award, running from July 2024 to June 2026, will also characterize and compare the subjective,...
The National Institute of Mental Health (NIMH) awarded a $633,671 Project Grant (CFDA 93.242 Mental Health Research Grants) to Rutgers, The State University of New Jersey, to evaluate the safety of prescription sleep medications in children, adolescents, and young adults with ADHD. The study will analyze nationwide patterns of sleep medication use and assess the risks of adverse outcomes, including suicide attempts, unintentional overdose, cardiovascular complications, and hallucinations. The...
This Project Grant award in the amount of $181,234 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will fund research to study the impact of early psychostimulant exposure on sleep neurophysiology and circadian rhythms in animal models of Attention-Deficit/Hyperactivity Disorder (ADHD). The research aims to break down the complex relationship between ADHD, psychostimulant medications like methylphenidate, and their...
This $570,550 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will investigate the effects of cannabidiol (CBD) on the driving performance, cognitive function, and collision risk of healthy adult participants aged 18-30. The 5-year study will involve a randomized, double-blind trial with 300 participants assigned to receive either a high dose of CBD (300 mg), a lower dose (150 mg), or a placebo. Participants...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $458,452 to the University of Utah to conduct research on the interrelationship between sleep and substance use disorders. The key objectives are to: Determine the mechanisms by which psychostimulants induce changes in sleep patterns, including anatomical and genetic investigations using the Drosophila model organism. Screen Drosophila...

CANNABIS EFFECTS ON SLEEP, CIRCADIAN RHYTHMS, AND LIGHT SENSITIVITY IN YOUNG PEOPLE - PROJECT SUMMARY PROBLEMATIC CANNABIS USE RATES HAVE INCREASED IN 'EMERGING ADULTHOOD' (AGE 18-25), AN AGE ALSO CHARACTERIZED BY HIGH RATES OF INSOMNIA AND THE DEVELOPMENTAL PEAK IN A TENDENCY TOWARD EVENINGNESS (PREFERENCE FOR LATER SLEEP TIMING). CANNABIS-SLEEP RELATIONSHIPS ARE INCREASINGLY RECOGNIZED AS PERTINENT FOR UNDERSTANDING RISK FOR CANNABIS MISUSE, PARTICULARLY GIVEN THE HIGH PREVALENCE OF CANNABIS USE AS A SLEEP AID. INSOMNIA AND AN EVENING CHRONOTYPE ARE RISK FACTORS FOR CANNABIS USE, AND CANNABIS USE AFFECTS SLEEP, BUT THE MECHANISMS UNDERLYING THESE CANNABIS-SLEEP RELATIONSHIPS ARE POORLY UNDERSTOOD. EXPERIMENTAL RODENT STUDIES IMPLICATE CANNABIS EFFECTS ON HOMEOSTATIC SLEEP DRIVE (INCREASED) AND CIRCADIAN PHOTOSENSITIVITY (REDUCED), ALTHOUGH SOME EFFECTS ARE EVIDENT ONLY IN MALES. HOWEVER, THESE MECHANISMS HAVE NOT BEEN SUFFICIENTLY INVESTIGATED IN HUMANS, WITH SCANT RESEARCH USING THE SLEEP EEG MEASURES NECESSARY TO ASSESS HOMEOSTATIC SLEEP DRIVE IN RELATION TO CANNABIS USE, AND NO PUBLISHED STUDIES EXAMINING CANNABIS EFFECTS ON CIRCADIAN PHOTOSENSITIVITY. IN RESPONSE TO RFA-DA-24-021, WE PROPOSE TO STUDY THE EFFECTS OF CANNABIS USE AND DISCONTINUATION ON SLEEP AND CIRCADIAN CHARACTERISTICS, INCLUDING SLEEP PHYSIOLOGY AND CIRCADIAN PHOTOSENSITIVITY, IN 60 EMERGING ADULTS (18-25 Y/O; 50% FEMALE) REPORTING REGULAR CANNABIS USE. WE WILL EXAMINE PARTICIPANTS THROUGHOUT A 1-WEEK BASELINE PERIOD OF REGULAR CANNABIS USE FOLLOWED BY A 4-WEEK CANNABIS DISCONTINUATION REINFORCED BY A CONTINGENCY MANAGEMENT PROTOCOL. HOMEOSTATIC SLEEP DRIVE WILL BE ASSESSED AT HOME USING SLEEP EEG HEADBANDS DURING BASELINE (ON BOTH NIGHTS OF CANNABIS USE AND NON-USE), AS WELL AS DURING EARLY AND EXTENDED ABSTINENCE DURING THE DISCONTINUATION. CIRCADIAN PHOTOSENSITIVITY AND CIRCADIAN PHASE WILL BE ASSESSED IN THE LABORATORY AT BASELINE AND AFTER DISCONTINUATION. A CONTROL GROUP OF 30 AGE- AND SEX-MATCHED HEALTHY-SLEEPING EMERGING ADULTS WITHOUT CURRENT CANNABIS USE WILL UNDERGO ALL BASELINE PROCEDURES. AIM 1 WILL EXAMINE THE EFFECTS OF CANNABIS USE AND DISCONTINUATION ON THE HOMEOSTATIC SLEEP DRIVE. AIM 2 WILL EXAMINE THE EFFECTS OF CANNABIS USE AND DISCONTINUATION ON CIRCADIAN PHOTOSENSITIVITY AND PHASE. AN EXPLORATORY AIM WILL EXAMINE SEX DIFFERENCES IN CANNABIS EFFECTS ON SLEEP, CIRCADIAN RHYTHMS, AND LIGHT RESPONSIVITY.

Posted 6/13/24, 12:00 AM